Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2010
18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 86 citations in OpenAlex.
- Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Do new guidelines enable a more accurate comparison of [Breast cancer research : BCR · 2026Article
- Correlation between Histopathological Prognostic Tumor Characteristics and [Diagnostics (Basel, Switzerland) · 2024Article
- Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors.Frontiers in immunology · 2022Article
- Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy.Molecular therapy oncolytics · 2021Article
- Diagnostic Performance of [Diagnostics (Basel, Switzerland) · 2021Article
- Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Relationship between Prognostic Stage in Breast Cancer and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.Journal of clinical medicine · 2021Article
- Radiogenomics Based on PET Imaging.Nuclear medicine and molecular imaging · 2020Review
- A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs.Medicine and pharmacy reports · 2019Review
- Article
- Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers.Cancers · 2018Article
- Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.European journal of nuclear medicine and molecular imaging · 2018Article
- Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.Oncotarget · 2018Review
- Texture analysis of high-resolution dedicated breastEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.European journal of nuclear medicine and molecular imaging · 2017Article
- Radiogenomic Analysis of Oncological Data: A Technical Survey.International journal of molecular sciences · 2017Review
- Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium.European journal of nuclear medicine and molecular imaging · 2017Article
- Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013.Nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
unlabelledPET imaging is useful for evaluating locally advanced primary breast cancer. Expression of specific molecular markers in these cancers, such as estrogen receptor (ER), progesterone receptor (PR), and HER2 status, has direct prognostic and therapeutic implications in patient management. This study aimed to determine whether a relationship exists between tumor glucose use and important molecular markers in invasive breast cancer. For our purposes, tumor glucose use is quantified by the PET-derived parameter maximum standardized uptake value (SUV).
methodsBreast tumors from 36 patients were excised and examined histologically after PET. ER, PR, and HER2 status were determined for all lesions histopathologically. In addition, genomewide expression for a subset of 20 tumors was analyzed using the human genome U133A oligonucleotide microarray.
resultsA significant association was found between estrogen ER status and lesion SUV. ER-negative tumors (n = 17; median SUV, 8.5) demonstrated a significantly higher maximum SUV than did ER-positive tumors (n = 19; median SUV, 4.0) (P < 0.001). No significant association existed between SUV and PR status, HER2/neu status, lymph node involvement, or tumor size. Unsupervised hierarchic clustering of the 20 genetically profiled cancers segregated tumor samples into 2 primary groups of 10 patients each, largely corresponding to ER status.
conclusionIn locally invasive primary breast cancer, ER-negative tumors display higher (18)F-FDG uptake than ER-positive tumors. Microarray analysis confirms these data and identifies genes associated with increased glucose use as measured by PET. These genes significantly overlap those of a previously validated ER-status molecular phenotype. These preliminary data support a growing body of evidence that ER-positive and ER-negative breast cancers have distinct disease-specific patterns. Further validation prospectively and with larger numbers will be required to establish a robust molecular signature for metabolic uptake and patterns of aggressive behavior in advanced breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.